CJC 1295 – 2mg (5 Vials)
History – What is CJC 1295?
CJC 1295 is a peptide that significantly increases plasma growth hormones and insulin growth factor levels within humans and animals alike. This peptide increases energy levels and induces faster metabolism making it incredibly helpful for those who desire to stay in good shape and exercise on a regular basis.
The Benefits of CJC 1295
Maximizes the amount of growth hormone being released into the body to reverse the negative effects of aging to enhance the human body and cause one to feel youthful by naturally:
- increasing muscle growth
- decreasing body fat
- improving sleep quality
- rejuvenating damaged tissues
- clearing elastosis
- strengthening immunity
CJC 1295 addresses growth hormone deficiency, however, those with cancerous tumors should avoid this peptide.
| Sequence | C152H252N44O42 |
|---|---|
| CAS | 446036-97-1 |
| Molecular Formula | C152H252N44O42 |
| Molecular Weight | 3367.9 g/mol |
| CID | 163285897 |
| Appearance | White Lyophilized Powder |
CJC-1295 No Dac Peptide – Otherwise Known As Modified Grf 1–29
Modified GRF (1-29), Modified Growth Releasing Factor 1–29, often abbreviated as mod GRF (1-29), originally known as tetrasubstitued GRF (1-29), is a term used to identify a 29 amino acid peptide analogue of growth-hormone-releasing hormone (GHRH), a releasing hormone of growth hormone (GH).
It is a modified version of the shortest fully functional fragment of GHRH, often referred to as growth hormone releasing factor (1-29) (abbreviated as GRF (1-29)), and also known by its standardized name, sermorelin.
Mod GRF (1-29) replacement of the 2nd, 8th, 15th, and 27th amino acids of GRF (1-29) yields modified GRF(1-29) (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2). Half-life at least 30 minutes.
The first 29 amino acids of GHRH were discovered to be as equally potent as its full 44 amino acid structure This fragment became known as GRF (1-29). However, due to a rapid metabolic clearance analogues of GRF (1-29) were synthesized to enhance the biological activity and reduce the rapidity of metabolic clearance. These analogues were primarily created by substituting amino acids within the peptide structure for amino acids more resistant to enzymatic cleavage.
One early analogue substituted the amino acid L-alanine (abbreviated as Ala or A) at the 2nd position of the peptide structure for its optical isomer (mirror image), D-alanine (abbreviated as D-Ala). This substitution resulted in a peptide bond between D-Ala and the 3rd amino acid in the structure aspartic acid (Asp) more able to resist rapid cleavage by the enzyme dipeptidyl peptidase-4, a cleavage which had previously led to an inactive peptide fragment.
This successful modification prompted the further creation of analogues with additional amino acid substitutions.
What Is DAC?
DAC stands for drug affinity complex and was developed by ConjuChem Biotechnologies. Why is it an important front runner for use in peptides? Well, typically peptides degrade over time whether that means as a natural peptide created in your body or a synthetic variation. The goal of DAC is to prevent this from happening all while keeping the same biological activity in the peptides.
In most cases, there are three parts to the construction of DAC. This includes the peptide itself, a link that is attached to the peptide, and a reactive group at the opposite end of the link. So when DAC is added to CJC 1295 it tends to make it degrade at a much slower pace which allows for cells to reap the many benefits of the peptide.
CJC-1295 With DAC vs. CJC-1295 No DAC
The biggest difference between CJC-1295 with DAC and CJC-1295 no DAC is that without DAC the peptide has a much shorter half-life of 30 minutes.
History of CJC 1295
CJC-1295 is a synthetic peptide that was developed in the early 2000s as a growth hormone-releasing hormone (GHRH) analog. It is designed to stimulate the release of growth hormone from the pituitary gland, which can lead to increased muscle mass, reduced body fat, and other benefits associated with growth hormone.
The development of CJC-1295 was led by ConjuChem, a Canadian biotechnology company. The company used a technology called “Chemical Synthesis Plus Conjugation” (CSPC) to create the peptide. This technology involves combining two peptides to create a larger, more stable molecule that can be administered as a single injection.
In 2005, ConjuChem partnered with Biogen Idec, a biotechnology company based in the United States, to develop CJC-1295 as a potential treatment for growth hormone deficiency and other conditions. However, the partnership ended in 2009 when Biogen Idec terminated the agreement due to concerns about the safety and efficacy of the drug.
Since then, CJC-1295 has been used primarily as a research tool in the scientific community. It has been studied for its potential to treat a variety of conditions, including growth hormone deficiency, obesity, and muscle wasting. However, its safety and effectiveness as a therapeutic agent have not been established, and it is not approved for use by the United States Food and Drug Administration (FDA) or other regulatory agencies around the world.
Learn more about CJC-1295 no DAC
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=CJC+1295
- ScienceDirect: https://www.sciencedirect.com/search?qs=CJC+1295
- Wiki: https://en.wikipedia.org/wiki/Modified_GRF_(1-29)
